موافقات الدواء

Hepatocellular carcinoma
Sorafenib is indicated for the treatment of hepatocellular carcinoma 
Renal cell carcinoma
Sorafenib is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha, or interleukin-2 based therapy or are considered unsuitable for such therapy.
Differentiated thyroid carcinoma
Sorafenib is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine.